Find an MSK Doctor or Cancer Specialist
Memorial Sloan Kettering medical oncologist Lorenzo Falchi

Lorenzo Falchi, MD

Lymphoma Specialist

My Role at MSK

Areas of Expertise

My Specialties

  • All non-Hodgkin and Hodgkin Lymphomas
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
View all
Dr. Falchi's Office Information
Languages: English & Italian

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
English
Share

About Me

What I Do at MSK
  • Assistant Attending Physician
Get To Know Me

As a board-certified medical oncologist and hematologist, I have been passionately dedicated to the study and treatment of blood diseases for well over a decade with a long-standing focus on the care of people with lymphoma. My practice benefits from years of experience that I gained while working at prestigious institutions.

Read more

At MSK, I am fortunate to be part of a multidisciplinary team of experts who share a deep commitment to developing effective therapies for all people with lymphoma. Our staff also provides an exceptional level of care and support for every one of our patients from the first point of contact, so that they are never alone during their time at MSK.

I am also deeply involved in conducting patient-centered research. At MSK, we offer one of the largest clinical trial portfolios for people with all types of lymphoma. I am especially interested in understanding how lymphoma interacts with the immune system. If we know how we can harness the immune system to fight lymphoma, we can develop new immunotherapies that can be used alone or in combination.

A lymphoma diagnosis can be overwhelming and terrifying. Most of my patients are naturally concerned about their future. I am convinced that the first step towards cure is defeating fear. That is why my priority is to clear up uncertainties by providing both information and education at every visit. I also believe that each person is unique, and my goal is to offer personalized care plans, while using the most effective and innovative treatments available today.

My Role at MSK

A lymphoma specialist is a doctor with special training in diagnosing and treating lymphoma.

Areas of Expertise

My Specialties

  • All non-Hodgkin and Hodgkin Lymphomas
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Marginal Zone Lymphoma
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
  • Peripheral T-Cell Lymphoma
  • Burkitt Lymphoma
  • Clinical Trials Research
  • Immunotherapy
  • Novel Therapeutic Agents
  • Personalized Therapy
Education & Honors

Education

  • MD, University of Perugia

Residencies

  • Internal Medicine - Yale-New Haven Hospital

Awards and Honors

  • Best Research Fellow for the Leukemia Fellowship Program, MD Anderson Cancer Center (2013)
  • Celgene Future Leaders in Hematology Award
  • American Society of Hematology Abstract Achievement Award (2018)

Fellowships

  • Medical Oncology - University of Perugia, Italy
  • Leukemia - MD Anderson Cancer Center
  • Hematology/Oncology - NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Internal Medicine
  • Hematology
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

MSK has a tentative agreement with Cigna to continue coverage in 2024.

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Women talking

New Patients

Scheduling an appointment is easy. Click or call 800-525-2225— we’re available Monday through Friday, to (Eastern time)
Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Falchi sees patients at two locations.

Office Phone
Location
New York, NY
Uniondale, NY
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
530 East 74th Street New York NY 10021
Get Directions
Memorial Sloan Kettering Nassau
1101 Hempstead Turnpike Uniondale NY 11553
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Lymphoma Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil LJ, Thieblemont C, Ursu R, Bartlett NL, Nachar VR, Weiss J, Osterson J, Patel K, Brody JD, Abramson JS, Lunning MA, Shah NN, Ayed A, Kamdar M, Parsons BM, Caimi P, Flynn IW, Herrera AF, Sharman JP, McKenna M, Armand P, Kahl BS, Smith SM, Zelenetz AD, Budde LE, Hutchings M, Phillips TJ, Dickinson M. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood. 2024 Jan 22:blood.2023022432. doi: 10.1182/blood.2023022432. Epub ahead of print. PMID: 38252906.
 

Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023 Feb 2;141(5):467-480. doi: 10.1182/blood.2021011994.

Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor OA. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021 Apr 22;137(16):2161-2170. doi: 10.1182/blood.2020009004. Erratum in: Blood. 2022 Mar 10;139(10):1600. PMID: 33171487.

Read more

Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O’Connor OA. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol. 2016 Nov 30;9(1):132. doi: 10.1186/s13045-016-0363-1. PMID: 27899158; PMCID: PMC5129196.

Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O’Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 1;123(18):2783-90. doi: 10.1182/blood-2013-11-536169. Epub 2014 Mar 10. PMID: 24615780; PMCID: PMC4123418.

Publications on PubMed

Visit PubMed for a full listing of Dr. Falchi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Lorenzo Falchi discloses the following relationships and financial interests:

  • ADC Therapeutics
    Professional Services and Activities
  • AbbVie
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • GenMab
    Professional Services and Activities
  • Genentech
    Professional Services and Activities
  • Physicians' Education Resource
    Professional Services and Activities
  • Projects In Knowledge
    Professional Services and Activities
  • Seagen
    Professional Services and Activities
  • Taylor & Francis Group
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: